Solid Biosciences (SLDB) said Wednesday it is teaming up with Mayo Clinic to advance an adeno-associated virus gene therapy platform to develop therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies.

The genetic medicine company said it will receive exclusive licenses to the Mayo Clinic's suppression and replacement gene therapy platform and to six cardiac gene therapy programs developed using the platform.

Solid said its AAV capsids and manufacturing capabilities will be used by the programs to suppress and replace genes implicated in potentially life-threatening genetic heart diseases.

Mayo Clinic will have the research and development responsibilities for the gene therapy candidates up to investigational new drug-enabling studies, at which point Solid can choose to continue the development of commercialization of each program.

Shares of Solid Biosciences were more than 6% higher in premarket trading.